Clinical characteristics associated with hospitalization and mortality of coronavirus disease-۲۰۱۹ (COVID-۱۹) infection in rheumatic patients: a cross-sectional study from Iran

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 151

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_RHRE-5-4_004

تاریخ نمایه سازی: 20 شهریور 1400

Abstract:

 This study was designed to describe COVID-۱۹ infection in rheumatic patients and to investigate possible risk factors for hospital admission and death related to COVID-۱۹ infection considering the type of rheumatic disease and medications used to treat it. In this observational cross-sectional study, patients under follow-up in Kermanshah rheumatology units were investigated in a ۶-month period between February ۱۸ and August ۲۲, ۲۰۲۰. Confirmed COVID-۱۹ cases were collected. The following data were obtained: age, sex, rheumatic disease diagnosis, rheumatic disease medication (glucocorticoids, csDMARDs, ts/bDMARDs). Rheumatic patients were divided into two groups of hospitalized and non-hospitalized. The data from the two groups were compared. In total, ۲۲۱ patients were enrolled in this study. Of these, ۳۸ patients (۱۷.۱۹%) were hospitalized, and ۹ patients (۴.۰۷%) died. No significant difference was observed between hospitalized and non-hospitalized patients except for vasculitis and prior use of Janus kinase inhibitors (Tofacitinib). A greater rate of hospitalized patients had vasculitis (۶ (۱۵.۷۹%) vs. ۱ (۰.۵۵%), p < ۰.۰۰۰۱ ). A greater rate of them were on Tofacitinib therapy (۲ (۱.۰۹%) vs. ۰, p value = ۰.۰۳). A greater rate of patients who died used Tofacitinib (۲ (۲۲.۲۲%) vs. ۰, p value = ۰.۰۰۱) and Mycophenolate Mofetil (۴ (۴۴.۴۴%) vs. ۲۳ (۱۰.۸۵%), p value = ۰.۰۱۴). Hospitalization and mortality rates in rheumatic patients are comparable to the general population. A higher risk for hospitalization was observed only in vasculitis patients and users of Tofacitinib, and a higher risk for mortality was seen only in users of Mycophenolate Mofetil and Tofacitinib, though this finding should be interpreted with caution due to the small size of these subgroups. In conclusion, most rheumatic patients do not seem to be at higher risk for severe COVID-۱۹. 

Authors

Shirin Assar

Rheumatology Department, Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Dena Mohamadzadeh

Rheumatology Department, Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Mehran Pournazari

Rheumatology Department, Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Parviz Soufivand

Rheumatology Department, Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.